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Abstract
Background: The aim of this investigation was to evaluate the anticancer activity of Noscapine (Nos) and Gemcitabine
(Gem) combination (NGC) against non-small cell lung cancer (NSCLC) and to elucidate the underlying mechanism of action.
Methods: Isobolographic method was used to calculate combination index values from cytotoxicity data. In vitro
antiangiogenic and apoptotic activity of Nos, Gem and NGC was evaluated. For in vivo studies, female athymic Nu/nu mice
were xenografted with H460 tumors and the efficacy of Nos, Gem, or NGC was determined. Protein expressions by
immunohistochemical staining were evaluated in harvested tumor tissues.
Results: The CI values (,0.59) were suggestive of synergistic behavior between Nos and Gem. NGC treatment showed
significantly inhibited tube formation and increased percentage of apoptotic cells. NGC, Gem and Nos treatment reduced
tumor volume by 82.964.5 percent, 39.465.8 percent and 34.265.7 percent respectively. Specifically, NGC treatment
decreased expression cell survival proteins; VEGF, CD31 staining and microvessel density and enhanced DNA fragmentation
and cleaved caspase 3 levels compared to single agent treated and control groups.
Conclusion: Nos potentiated the anticancer activity of Gem in an additive to synergistic manner against lung cancer via
antiangiogenic and apoptotic pathways. These findings suggest potential benefit for use of NGC chemotherapy for
treatment of lung cancer.
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Introduction
Lung cancer is the leading cause of cancer-related deaths.
Majority of patients diagnosed with lung cancer present with locally
advanced or metastatic disease [1,2]. More than 85 percent of
patients with lung cancer have non-small cell lung cancer (NSCLC).
Majority of newly diagnosed NSCLC patients present with disease
beyond the scope of surgical cure and depend on systemic
chemotherapy to improve their outcome [3,4]. Platinum based
combinationregimens are first-line treatment option in treatment of
NSCLC but their clinical utility has been limited due to substantial
toxicities [4,5]. Despite recent advances in chemotherapy, response
rates in NSCLC remain ,50 percent and a third of patients with
stage IV disease have a 2-year survival rate of ,20 percent [3]. The
establishment of an optimal regimen for combination therapies with
currently used and newly developed drugs is an important step to
achieve higher response and longer survival [6]. To address this
problem, attention has been focused on finding novel anticancer
agents that will deliver equivalent or improved survival to that
achieved with platinum regimens, but with less toxicity. Gemcita-
bine (Gem) is a pyrimidine nucleoside antimetabolite agent which is
active against variety of human malignancies, including NSCLC
with a favorable toxicity profile [6,7]. Several researchers have
studied the combination of Gem and cisplatin, topotecan, protease
inhibitors, and ginsenoside Rg3 for the treatment of lung cancer
[8,9,10,11,12]and reported enhanced anticancer effects [8,9,10,11,
12,13].
The anticancer activity of microtubule-interfering agents,
taxanes and vinca alkaloids has been well studied [14]. However,
the clinical utility of taxanes has been limited due to drug-
resistance, need of intravenous (i.v.) infusion over a long period
of time and associated toxicities [15,16]. This has prompted
search for microtubule-targeting agent that may be administered
orally, display favorable toxicity profiles and have better
therapeutic indices. Nos attenuates microtubule dynamics just
enough to activate the mitotic checkpoints to stop cell cycle
[17,18] and demonstrated anti-proliferative activity against wide
variety of cancer cells including many drug-resistant variants
while evading normal cells [18,19,20,21,22,23,24,25,26]. Fur-
thermore, Nos also showed little or no toxicity to the normal
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in mice [19,20]. Our previous studies demonstrated that oral
administration of Nos showed significant anticancer activity in a
dose-dependent manner against H460 lung tumor xenografts
[24]. Landen et al. demonstrated that there was no significant
improvement in the anticancer activity of Nos when combined
with paclitaxel[19] possibly due to competition for the same
target. The use of Nos in combination with vincristine exhibits
synergistic antitumor effects in leukemia cells in vitro [27].
However, anticancer potential of Nos in combination with
various anticancer agents in the treatment of lung cancer has not
been systematically explored. Both Nos and Gem have different
mechanism of action and Nos and Gem combination (NGC)
may lead to potential synergistic antitumor activity against lung
cancer.
Based on the individual activity of these agents and their distinct
mechanisms of action, we hypothesized that NGC may produce
additive to synergistic cytotoxic effects in human lung cancer cells
in vitro and in vivo possibly by degradation of specificity proteins,
enhancing antiangiogenic and apoptotic activity. In present
investigation, we evaluated anticancer activity of NGC therapy
against NSCLC cells in vitro and in vivo in H460 murine
xenograft lung tumor model which has not been reported before.
The objectives of this study were to (a) examine the anticancer
activity of combination of between Nos and Gem against NSCLC
cells, and (b) evaluate the antitumor effect of NGC in mice bearing
H460 xenograft lung tumors and elucidate underlying mechanism
of action.
Materials and Methods
Materials
Noscapine and Gemcitabine were purchased from Sigma
Chemicals, St. Louis, MO, USA and Spectrum Chemicals USA
respectively. The human H460 and A549 NSCLC cells were
obtained from American Type Culture Collection (Rockville, MD,
USA). All other chemicals were either reagent or tissue culture
grade. H460 and A549 cells were grown in RPMI 1640 medium
and F12K medium (Sigma, St. Louis, MO, USA) supplemented
with 10 percent fetal bovine serum respectively. All tissue culture
media contained antibiotic antimycotic solution of penicillin
(5000 U/ml), streptomycin (0.1 mg/ml), and neomycin (0.2 mg/
ml). The cells were maintained at 37uC in the presence of 5
percent CO2 in air.
Animals
Female Nu/Nu mice (six weeks old, Harlan, Indianapolis, IN)
were grouped and housed (8/cage) in sterile microisolator caging
unit supplied with autoclaved Tek-Fresh bedding. The animals
were housed at Florida A and M University in accordance with the
standards of the Guide for the Care and Use of Laboratory Animals and the
Association for Assessment and Accreditation of Laboratory
Animal Care. The present study was reviewed and approved by
Florida A and M University (FAMU) Animal Care and Use
Committee (AUCU) August, 2009. (Protocol # 002-09).
In vitro cytotoxicity studies
The A549 or H460 cells were plated in 96-well micro titer
plates, at a density of 1610
4 cells/well and allowed to incubate
overnight. The cells were treated with various dilutions of Gem in
the presence or absence of Nos at 10–30 and 30–50 mM against
H460 and A549 cells respectively. The plates were incubated for
72 h at 3760.2uC in a incubator. Cell viability in each treatment
group was determined by crystal violet dye assay.
Induction of apoptosis in H460 and A549 cells
The H460 or A549 cells were plated at a density of 1610
6 cells/
well in 6-well plates and incubated overnight. H460 cells were
treated with Gem (0.4 mg/ml), or Nos (30 mM), or NGC and A549
cells were treated with Gem (0.3 mg/ml), or Nos (50 mM), or
NGC. After 72 h, cells were fixed in 4% paraformaldehyde and
mounted onto slides using Cytospin R (Shandon) and processed as
per ApoTag Red In Situ Apoptosis detection kit R (Chemicon R
International, CA, USA) protocol. The images on the slides were
visualized with an Olympus BX40 fluorescent microscope. To
quantify the apoptotic cells, 100 cells from 6 random microscopic
fields were counted.
Inhibition of tube formation of HUVEC cells in vitro
The antiangiogenic effects of Nos and Gem were analyzed using
an In Vitro Angiogenesis Assay Kit (Millipore, Billerica, MA, USA).
Briefly, HUVEC cells were cultured in the presence or absence of
30 mM Nos, 0.4 mg/ml Gem and NGC on polymerized Matrigel
at 37uC. Standard Matrigel was allowed to polymerize in a 96-well
plate and HUVEC cells were seeded at a density of 3610
4 per well
in ECM medium. After 6 h, tube formation by endothelial cells
was evaluated and photographed. Quantification of progression of
angiogenesis was accomplished by counting the capillary tube
branch points formed after a set amount of time (end-point assay).
Branch points in several random view-fields (3–10) per well should
be counted and the values averaged.
In-vivo antitumor effect of Nos against H460 lung tumors
The adherent H460 cells were harvested and centrifuged at
500 g for 4 min at 4uC and the cell pellet was resuspended. The
cells were diluted to 3610
6 cells/100 ml using growth medium.
The 100 ml of cell suspension was injected subcutaneously into
right flank area of each mouse. The protocol for in-vivo
experiments with nude mice was approved by the Animal Care
and Use Committee, Florida A and M University, Tallahassee,
FL. The mice were randomized (n=8) after 50 mm
3 of tumor
xenografts (7 days post tumor implantation) and treated with i)
160 ml of vehicle (Phosphate buffer, pH 3.5); ii) Gem (30 mg/kg
i.v. bolus, q3d 67 schedule); iii) Nos 300 mg/kg daily by oral
gavage; and iv) NGC therapy for 38 days post tumor implantation.
Noscapine was dissolved in phosphate buffer, pH 3.5 and
Gemcitabine was dissolved in the saline phosphate buffer before
administration to mice. To check for evidence of toxicity, the
animals were weighed twice weekly. The tumor dimensions were
measured using a linear caliper and tumor volume was calculated
using following equation:
V(mm
3)~(a)x(b
2=2) ð1Þ
where,
v=tumor volume
a=largest diameter of tumor
b= smallest diameter of tumor
On day 38, all animals were sacrificed following removal of the
tumor tissues; some of the tumors were fixed in formalin while
others were rapidly frozen in liquid nitrogen and stored in 280uC.
Western Blotting of Tumor Tissues
The proteins were extracted from tumor tissue using RIPA
buffer with protease inhibitor incubated for 30 min on ice and the
supernatants were stored at –80uC after centrifugation. For
western blotting (WB), a previously established procedure in the
laboratory was used. [24,28] The membranes were probed with
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(1:750), Sp3 (1:750), VEGF (1:500), pAKT (1:500), Cyclin
D1(1:500), p53 (1:500), p21 (1:500),), PARP (1:1000), cleaved
PARP (1:1000), cleaved caspase 3 (1:1000), caspase 8 (1:1000) and
caspase 9 (1:1000), Bax (1:1000), Bcl2 (1:1000), BID (1:500) and b-
actin antibodies (1:500). Bound antibodies were revealed with
HRP conjugated secondary antibodies (1:2000) using SuperSignal
West pico chemiluminescent solution (Pierce, Rockford, IL). Beta
actin protein was used as a loading control. The densitometric
analysis of the bands was performed using the program ImageJ
v1.33u.
TUNEL Assay, Cleaved Caspase 3 expression and
VEGFexpression
The TUNEL, cleaved caspase-3 and VEGF staining in paraffin-
embedded tumor tissues sections were evaluated using Dead-
EndTM Colorimetric Apoptosis Detection System (Promega,
Madison, WI), cleaved caspase-3 staining kit (Cell Signaling
Technology, Beverly, MA) and ImmunoCruz
TM ABC Staining
System (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
respectively as described previously [26]. Tumor tissue sections
(4–5 mm thick) mounted on poly-L-lysine–coated slide were
deparaffinized by xylene and dehydrated through graded
concentrations of alcohol, then incubated with 3 percent hydrogen
peroxidase for 20 min to block endogenous peroxidase activity.
Antigen retrieval for staining and blocking of endogenous
peroxidase was performed as described previously [26]. The
samples were incubated overnight at 4uC with 1:50 dilution of
primary antibody incubated with biotinylated secondary antibody
followed by streptavidin. The color was developed by exposing the
peroxidase to a substrate-chromagen, which forms a brown
reaction product. The sections were then counterstained with
hematoxylin. Three slides per group were stained and TUNLE,
cleaved caspase 3 stained cells were identified by dark brown
cytoplasmic staining. The VEGF stained cells were identified by
brown staining. The images on the slides were visualized with an
Olympus BX40 light microscope.
CD31 Expression and Assessment of Microvessel Density
For CD31 expression after washing with PBS, the sections were
pretreated in citrate buffer in a microwave oven for 20 min at 92–
98uC. After two washes with PBS, specimens were incubated in 10
percent normal goat serum (Atlanta Biologicals, GA, USA) for
20 min to reduce the nonspecific antibody binding. Subsequently,
the sections were then incubated with a 1:500 diluted mouse
CD31 monoclonal antibody (Cell Signaling Tech, MA), which is
recognized as an endothelial cell surface marker, at room
temperature for 1 h, followed by a 30 min treatment with HRP
Rabbit/Mouse (Santa Cruz Biotechnology, CA, USA). The
section was developed with diaminobenzidene-hydrogen peroxi-
dase substrate, and lightly counterstained with hematoxylin. To
calculate microvessel density (MVD), three most vascularised areas
of the tumour (‘hot spots’) were selected and mean values obtained
by counting vessels. A single microvessel was defined as a discrete
cluster of cells positive for CD31 staining, with no requirement for
the presence of a lumen. Microvessel counts were performed at
X400 (X40 objective lens and X10 ocular lens; 0.74 mm
2 per
field).
Statistics
One-way ANOVA followed by Tukey’s Multiple Comparison
Test was performed to determine the significance of differences
among groups using GraphPad PRISM version 3.0 software
(SanDiego, CA). Differences were considered significant in all
experiments at P,0.01 (*, significantly different from untreated
controls;
**, significantly different from Nos and Gem single
treatments.
Results
Synergistic in vitro cytotoxicity of NGC treatment
In vitro cytotoxicity studies with Nos against H460 and A549
cells showed IC50 values of 34.762.5 mM and 61.2565.6
mM respectively. Gem showed IC50 of 0.760.1 mg/ml and
0.660.2 mg/ml against H460 and A459 NSCLC cells. The
combined effects of Gem and Nos on cell proliferation was
evaluated by isobolographic analysis. The CI values ranged from
0.3460.02 to 0.5960.04 for 50 percent cell kill suggesting
synergistic to strong synergistic behavior between Nos and Gem
against both NSCLC cell lines (Fig 1A). Isobolograms for the 50%
effect level show that the IC50-equivalent concentrations for
various Nos/Gem combinations were located below the line of
additivity, indicating synergistic activityof Nos and Gem combi-
nation (Fig. 1B). The separation of the points in the isobologram
was consistent with that of the CI values.
Antiangiogenic effect- tube formation assay
Nos (30 mM), Gem (0.3 mg/ml) and 30 mM Nos + 0.3 mg/ml
Gem treatment for 6 hr showed poor organizationof HUVEC
tube-like structures and a decrease in capillary tube branch point
formations (Fig. 2A) compared to control group which showed a
rich meshwork of branching anastomosing capillary-like tubules
with multicentric junctions (Fig. 2). NGC treatment decreased
formulation of average branching point by 6865 percent
compared to 2663 percent by Nos alone and by 2964 percent
Gem alone (Fig. 2B).
Induction of apoptosis in H460 and A549 cells
Fig. 2C shows that apoptosis is induced in H460 and A549 cells
following treatment with Gem, or Nos, or NGC. NGC treatment
led to apoptosis in 5964 percent of treated H460 cells compared
to 2763 percent and 2062 percent in Gem and Nos respectively
after 72 hr (Fig 2D and 2E). Similarly, NGC treatment of A549
cells led to 6765.0 percent apoptotic cells compared to 3262.0
percent and 2063.0 percent in Gem and Nos respectively (Fig 2D
and 2E). All treatments were significantly different from control
(* P,0.01). Gem or Nos treatment was significantly different from
NGC treatment (**, P,0.001).
Anti-tumor activity of NGC in H460 xenografts
The results (Fig. 3) show that tumor volume significantly
decreased after treatment with Gem, Nos, or NGC compared to
control. Tumor volume for the NGC treatment averaged
418.74655.53 mm
3 compared with 1605.086253.29 mm
3 for
Nos treatment or 1498.336149.38 mm
3 for Gem treatment
(tumor volume 6 SE) on day 38 post tumor implantation.
Furthermore, we did not observe any weight loss or other signs of
toxicity in the mice treated with NGC or Nos or Gem.
Effects on specificity proteins, angiogenic and apoptotic
proteins in H460 xenograft lung tumors
The NGC and Gem decreased expression of Sp1 and Sp3 in
harvested tumors compared to control mice (Fig 4). NGC
treatment decreased expression of VEGF protein expression to
0.26-fold compared to 0.12-fold with Nos and 0.13-fold with Gem
treatment, respectively of controls in regressed tumors (Fig 4). The
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fold, 0.29 fold and 0.37 fold with NGC, Gem and Nos treatment
compared to control group respectively (Fig 4). The NGC showed
significant decrease in expression of pAKT compared to control
group. In regressed tumors, the NGC and Gem significantly
decreased Cyclin D1 expression to a 0.39, 0.20, and 0.15-fold,
respectively of controls (Fig 4). Nos, Gem and NGC treatment
significantly increased p53 expression to 1.2, 1.3 and 1.6-fold in
regressed tumor samples compared to control respectively. (Fig 4)
Expression of p21 was significantly increased to 1.31-fold with
NGC treatment compared to 1.15 and 1.13-fold with Nos and
Gem treatment respectively (Fig 4). Results illustrated in Fig 5
show that Nos, Gem and NGC treatment showed significant
increased expression of cleaved PARP, Bax, BID, caspase 3,
cleaved caspase 3, caspase 8 and caspase 9, and decreased
expression of PARP and Bcl2 compared to control group. The
expression of apoptotic and antiapoptotic proteins in NGC
treatment was significantly different from single agent treatment
groups.
DNA fragmentation and cleaved caspase-3 expression in
tumor tissue
Single-agent treatment with either Nos or Gem induced DNA
fragmentation that was further significantly (** P,0.001) increased
by NGC treatment. The NGC treatment led to apoptosis in
8065.0 (** P,0.01) percent of the tumor cells, whereas Nos and
Gem induced apoptosis in 3463.0 percent and 4264.0 percent of
the tumor cells respectively (Fig. 6). Gem, Nos, and NGC induced
cleaved caspase-3 expression in tumors which was significantly
different compared to control tumors. NGC, Gem and Nos
treatment showed 6264.0, 3462.0, and 266 2.0 percent
increased expression of cleaved caspase 3 in tumors tissues
respectively compared to control group (Fig. 6).
Inhibition of angiogenesis and MVD in tumor tissue
The highest expression of VEGF was seen in tumor tissues
harvested from untreated mice (Fig. 6). Decreased VEGF staining
was observed in tumors treated with NGC (0.28-fold) compared to
tumors treated with Gem (0.15-fold) or Nos (0.1-fold) alone. This
response was well correlated to down-regulation of VEGF protein
observed in tumor lysates from mice treated with the same
compounds (Fig. 4). CD31 (+) endothelial cells were identified
using IHC technique in harvested tumor tissues and the results are
shown in Fig. 6. The staining of microvessels in NGC, Gem and
Nos treated groups were significantly decreased to 0.21, 0.08, and
0.06-fold compared to control group. The average microvessel per
field in groups treated with Nos, Gem and NGC were found to be
148.7618.6, 135.3617.5, and 91.8 6.1 respectively compared to
197.7622.4 in control group.
Discussion
Poor clinical outcome of the current chemotherapy necessitates
search for newer therapeutic strategies for the treatment of
NSCLC [1,3,4]. The development of potent nonplatinum based
combination chemotherapy with fewer adverse side effects will
help to improve the clinical outcome among lung cancer patients
[3,4,5]. The use of promising anti-microtubular agents has been
Figure 1. Isobolograms (A) and (B) Combination Index (CI) values of the interaction between Gem with Nos against human lung
Cancer cells. Different concentrations of Nos were employed to study the effect on IC50 of Gem. Variable ratios of drug concentrations and
mutually non-exclusive equations were used to determine the CI. The CI values represent mean of four experiments. CI .1.3: antagonism; CI 1.1–1.3:
moderate antagonism; CI 0.9–1.1: additive effect; CI 0.8–0.9: slight synergism; CI 0.6–0.8: moderate synergism; CI 0.4–0.6: synergism; CI 0.2–0.4: strong
synergism.
doi:10.1371/journal.pone.0027394.g001
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associated adverse side effects [15,16]. Nos is a safer orally active
microtubule agent [19,20,23] and has exhibited in-vitro and in-
vivo antitumor activity against variety of cancers [19,20,21,22,23].
Our previous studies demonstrated that Nos exhibited anticancer
activity in murine H460 xenograft model with no adverse side
effects [24]. Gem is one of the most effective agents against lung
cancer which inhibits DNA synthesis and ribonucleotide reductase
[6,7]. Thus, it is expected that NGC chemotherapy may exert
additive or synergistic anticancer activity and will have lower
adverse side effects due to reduced dose requirement for Gem.
The fast growing H460 and slow growing A549 cells [28] were
selected to ascertain activity of Nos and Gem combination at sub
IC50 concentrations using commonly used isobolographic method
Figure 2. Tube formation assay with HUVEC cells after 6 h (A); quantification of branching points (B); micrographs of cells stained
with TUNEL after 72 h (C) and quantitation of apoptotic H460 (D) and A549 cells from TUNEL assay (E). For tube formation assay,
HUVEC cells were incubated with Nos (30 mM), Gem (0.4 mg/ml) and NGC on polymerized Matrigel at 37uC. After 6 h, tube formation by endothelial
cells was photographed and the capillary tube branch point formation were quantified (n=3). For TUNEL assay, H460 cells were treated with Gem
0.4 mg/ml, Nos 30 mM, and, NGC and A549 cells were treated with Gem 0.3 mg/ml, Nos 50 mM, and, NGC. Control cells were untreated. Micron bar
=10mm. Cells were quantitated by counting 100 cells from 6 random microscopic fields. Data are expressed as mean + SD (n=6).
doi:10.1371/journal.pone.0027394.g002
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the data showed that Nos enhanced the cytotoxicity of Gem (CI
values ,0.59) in A549 and H460 human NSCLC cells in a
synergistic manner (Fig 1A). The synergistic activity was also
observed in the isobologram, where IC50-equivalent concentra-
tions for various NGC were located below the line of additivity
(Fig 1B). We recently reported that the CI values ,1.0 are
indicative of synergistic activity between DIM-C-pPhC6H5and
Docetaxel in NSCLC cells [28].
To study the possible mechanism involved in the enhanced
cytotoxicity of Gem by Nos, we evaluated HUVEC tube
formation and apoptosis of tumor cells [31]. Newcomb et al.
reported that Nos (0–150 mM) inhibited in vitro tube formation in
2H11 endothelial cells [32]. Similarly, Laquente et al also
demonstrated inhibition of proliferation of HUVEC cells by
Gem [33] and hence, we have evaluated the antiangiogenic
potential of NGC. There has been no study so far to evaluate the
effect of GNC on HUVEC tube formation. NGC showed the
linear structures of the network were significantly disrupted
compared to single agent treatment or controls. NGC exhibited
synergistic anti-angiogenic activity by inhibition of tube formation
compared to Nos or Gem alone (Fig 2).
Induction of apoptosis is key mechanisms of anticancer agents
and the significant induction of apoptosis which was evident from
positive TUNEL staining and chromatin condensation in NGC
treatment compared to single agent. Similar to our results,
combination treatment of Nos (150 mg/kg/day by gavage) and
60Co radiation (single fraction - 25 Gy) showed significant
(P,0.01) increased TUNEL positive GL261 cells compared to
single agent treatment [33].
Having established the effectiveness of the NGC treatment in
vitro, we next evaluated the in vivo antitumor efficacy of NGC in
H460 xenograft lung tumors in Nu/nu mice. We selected sub-
therapeutic doses of Nos (300 mg/kg/dayand Gem (30 mg/kg i.v.
bolus, i.v. bolus, q3d 67 schedule) based on our previous studies
which have demonstrated dose dependent anticancer activity
(300,450 ,550 mg/kg/day) of Nos against H460 xenograft
murine model [24]. Our in vivo results demonstrate additive
behavior of NGC in murine H460 xenograft tumor model (Fig 3A).
Previous reported studies demonstrated that anticancer activity of
Nos varies with the type and sensitivity of cancer cells [19,20,21].
Interestingly, NGC treatment showed non-significant change in
weight loss suggesting favorable toxicity profile of Nos and Gem.
NGC treatment will be advantageous over conventional Gem +
taxane treatment of lung cancer due to improved patient
compliance by oral administration of Nos with minimal adverse
side effects. Several studies have provided evidence that enhanced
tumor growth inhibition can be achieved by combining Gem with
other agents such as bortezomib [34], Telomelysin [35],
Dihydroartemisinin [36], Paclitaxel [37], and topotecan [38]
compared to single agent treatment. The in vivo additive activity of
NGC treatment may be attributed to poor bioavailability (,30%),
shorter plasma half life (,4.5 h) and extensive first-pass metab-
olism of Nos reducing the availability Nos at the tumor site
[39,40,41]. Our future studies will focus on improving the
bioavailability of Nos to explore its anticancer potential in
combination with Gem.
Based on in vitro antiangiogenic and apoptotic activity we have
evaluated the expression of Sp proteins, cell survival, VEGF and
apoptotic proteins. Sp proteins are transcription factors which are
overexpressed in many human tumors [42,43]. Lou et al.
demonstrated that transformation of fibroblasts resulted in
increase in Sp1 expression by 8 to 18-fold and showed formation
of highly malignant tumors in athymic xenograft models [44]. For
the time time, we showed that NGC treatment showed significant
(p,0.01) decrease in the expression of Sp1 and Sp3 proteins
compared to single agent treatment and control group. Previous
studies demonstrated that VEGF expression is partially dependent
on Sp proteins [45], and there is also evidence that survivin
expression is Sp dependent [46]. Gem, Nos and NGC treatment
decreased expression of survivin in lung tumors (Fig 4A and 4B).
Survivin is a member of the inhibitor of apoptosis family which
inhibits caspase activation and acts as a negative regulator [46].
Therefore, the down-regulation of survivin expression results in
activation of caspases and thereby induces apoptosis in tumor cells.
We also observed that NGC treatment significantly decreased
expression of VEGF (Fig 4D) in regressed tumors compared to
single agent treatment. Similarly, Papineni et al demonstrated that
Tolfenamic acid inhibits esophageal cancer through repression of
Sp proteins and several Sp-dependent genes and proteins such as
VEGF, survivin, cyclin D1 and Bcl-2 [47]. Nos alone and NGC
treatment showed decreased expression of VEGF and survivin,
which may be correlated to degradation of Sp1 and Sp3.
Furthermore, our IHC results show that NGC treatment
decreased VEGF and CD 31 staining in tumor tissues harvested
from mice compared to single agent treatment and control
(Fig 6A). The tumor regression by NGC was also mediated
through decreased expression of VEGF and CD 31 and correlated
Figure 3. Effects of Nos, Gem and NGC on human H460 lung tumor xenograft model (A) progression profile of tumor growth
kinetics and (B) tumor volume measurements on days 38 post-inoculation (tumor volumes, mm3 ± SEM). The mice were treated with
Gem 30 mg/kg i.v. bolus, q3d 67 schedule, Nos 300 mg/kg/day, and NGC. Control group received vehicle only. Data presented are means and SE
(n=8). This experiment was repeated twice.
doi:10.1371/journal.pone.0027394.g003
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lysates (Fig. 4D) and inhibition of tube formation (Fig 2). MVD is a
commonly used index of tumor angiogenic activity and the
average microvessels per field (Fig. 6B) in NGC treated group were
significantly (p,0.001) decreased compared to the single agent
treated and control group.
Previous studies demonstrated that Nos induces multiple
proapoptotic responses that induce apoptosis against variety of
tumors [19,20,21]. Activation of p53 protein plays a crucial role in
the control of tumor cell response to drugs and Bax and p21 are
downstream effectors proteins. [48]. Bax, BID and p21, were
activated in NGC treatment producing apoptosis in lung tumors
cells. In support of our data, Aneja et al demonstrated that
anticancer activity of Nos against colon cancer cells was mediated
via p53-dependent pathway [48]. Furthermore, the decreased
expression of cyclin D1 suggests involvement of ubiquitin/
proteosome system in induction of apoptosis by NGC. Ubiqui-
tin/proteosome system regulates various cell cycle regulators and
Figure 4. Expression of VEGF, SP1, SP3, pAKT, cyclin D1, p53, p21, and survivin proteins in tumor lysates by western blotting (A)
and (B) quantitation of apoptotic protein expression. Lane 1, untreated control tumors; lane 2, oral Nos 300 mg/kg; lane 3, Gem 30 mg/kg i.v.
bolus, q3d 67 schedule ; lane 4; NGC. b-actin protein acts as a loading control. Similar results were observed in triplicate experiments. Protein
expression levels (relative to b-actin) were determined. Mean 6 SE for three replicate determinations.
doi:10.1371/journal.pone.0027394.g004
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kinase inhibitors. In addition, we also observed that Gem, Nos and
NGC decreased cell survival proteins pAKT in lung tumors (Fig 5).
Caspases are critical protease mediators of apoptosis triggered by
different stimuli [29]. The NGC treatment activated initiator
caspases, such as caspase-8 (intrinsic pathway) and caspase-9
(extrinsic pathway) followed by activation of effector caspase-3.
Consistent with our results, Schniewind et al demonstrated
enhanced cytotoxicity of phenylbutyrate and Gem therapy against
KNS62 and Ben NSCLC cells via intrinsic apoptotic pathways
[49]. Results of our in vivo studies also demonstrate that Gem and
Nos alone and NGC treatment induce Bax expression and
decrease survival (Bcl2) proteins (Fig 5). These results also suggest
that apoptosis may be mediated through the mitochondrial
pathway via down-regulation of antiapoptotic Bcl2 and up-
regulation of proapoptotic Bax [24]. DNA fragmentation was
Figure 5. Expression of apoptotic PARP, cleaved PARP, caspase 3, cleaved caspase 3, caspase 8, caspase 9, Bax, Bcl2, and BID
proteins in tumors (A) and (B) quantitation of apoptotic protein expression. Lane 1, untreated control tumors; lane 2, oral Nos 300 mg/kg;
lane 3, Gem 30 mg/kg i.v. bolus, q3d 67 schedule ; lane 4; NGC. b-actin protein acts as a loading control. Similar results were observed in replicate
experiments. Protein expression levels (relative to b-actin) were determined. Mean 6 SE for three replicate determinations.
doi:10.1371/journal.pone.0027394.g005
Figure 6. Immunohistochemical staining of H460 tumor tissues for VEGF, CD31, TUNEL assay and cleaved caspase 3 expression (A)
and (B) quantitation of quantization of VEGF, assessment of microvessel density, quantitation of TUNEL positive cells and cleaved
caspase 3 positive cells. Data are expressed as mean + SD (N=6).
doi:10.1371/journal.pone.0027394.g006
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or Gem alone thus confirming that apoptosis is one of the
underlying mechanism, which is in agreement with our in vitro
TUNEL assay results and western blots results of tumor lysates
(Fig. 5). Our previous studies also demonstrated induction of
apoptosis and activation of cleaved caspase 3 following Nos
treatment in NSCLC [24]. Our findings suggest that the activation
of extrinsic and intrinsic apoptotic pathways plays a critical role in
the cytotoxicity of NGC treatment against NSCLC. To gain more
insights on the anticancer mechanisms of NGC therapy, other
non-apoptotic signaling pathways need to be investigated which
are in progress.
In conclusion, our results demonstrate that NGC therapy is
highly effective for inhibiting lung tumor growth in a murine lung
xenograft model. The antitumorigenic activity of Gem was
enhanced by Nos through degradation of Sp proteins, inhibition
of angiogenesis, and induction of apoptosis via intrinsic and
extrinsic pathways in lung tumors. Thus the use of NGC therapy
could be an innovative and promising therapeutic strategy for the
treatment for lung cancer and possibly will have fewer adverse side
effects compared to currently available platinum based chemo-
therapy.
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